Treatment Registry
TR-0483 Not verifiedRecorded September 2026

Oral semaglutide

Recorded for Revel Health · Sublingual · every oral semaglutide record

Price

Historical price evidence from September 2026. Current availability and prices are not verified. These figures are not a current offer.

TermPublished rateCharged today
Semaglutide ODT, from-price, first month discounted

Price conditions have not been established; the quoted figure is not a verified recurring rate.

“Semaglutide ODT From $149 /mo First month $99”

$149Published figureCharged todayNot verified
Price sources
Provider website · Revel Health

Current availability of this program is not verified.

We earn nothing from this link. It opens Revel Health's website without a paid referral.

History

Fewer than two comparable calendar-month readings are available for a price trend. Day- or week-based supplies, introductory offers and unverified payment terms are not connected in this chart.

  • September 2026 — Entry added to the register

Sourcing and terms

StatesAll states except Alaska, Arkansas, Mississippi, New Jersey, and North Carolina
PrescriberAsynchronous review
CancellationWhat happens if I'm not approved? If a licensed provider determines that a program is not appropriate for you, you'll be notified and receive a full refund. Any subscription will be canceled, so there are no ongoing charges.

Not yet checked: pharmacy, membership and consult fee.

Recorded from myrevelhealth.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.

Notes

  1. 1. September 2026 — Clean per-product pricing for four SKUs: semaglutide injection, semaglutide ODT (orally-dissolving tablet, classified as sublingual since it melts rather than being swallowed), tirzepatide injection, and tirzepatide ODT. All state list on the homepage is an explicit served-list (44 states), not an exclusion, with the 5 unserved states named separately.
  2. 2. October 2026 — The provider homepage and earlier weight-loss catalog now lead to a password-protected storefront labeled “Coming Soon.” Current treatment availability, prices, prescribing, pharmacies, service area and financial terms could not be verified from the public storefront. Earlier observations remain historical information, not confirmed current offers. This access limitation does not establish that the company or any treatment has been permanently discontinued.

Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.

This record

Entry
TR-0483
Medication category
oral semaglutide
Readings
1

Related records

Cite this entry

Treatment Registry. (2026). Revel Health — oral semaglutide (TR-0483). Last verified September 2026. Retrieved [your access date], from https://treatmentregistry.com/registry/TR-0483

Replace the bracket with the date you read it. Ours is the date we last checked the figures, which is a different thing and is given separately.